Hotwire Ignite Possibility Program Introduces the First Group of Tech-enabled DEI Innovators
30.6.2021 16:00:00 EEST | Business Wire | Press release
Hotwire, the leading global technology communications consultancy part of Enero Group, has announced the first set of participating companies in the Hotwire Ignite Possibility Program (HIPP). Launched earlier this year, HIPP is providing $1 million USD in pro bono brand marketing and public relations services to tech and tech-enabled organizations led by or supporting minority communities. This program is part of Hotwire’s Diversity, Equity, and Inclusion (DEI) strategy to amplify people and organizations creating meaningful and sustainable change in the world through technology innovation.
After a rigorous review process of nearly 100 applicants, including in-depth interviews with a short list of finalists, the first group of participating companies includes for-profit and nonprofit organizations in the consumer and B2B technology industries with headquarters in the United States and United Kingdom. HIPP participants from our other European offices and Australia will be announced in the coming months.
The six initial participating companies are:
- Children’s Creativity Musuem , a nonprofit organization offering hands-on, multimedia arts and technology experiences to build children’s creative confidence.
- Full Circle Fund , a nonprofit community leveraging professionals’ financial and intellectual capital to accelerate nonprofits and build a better San Francisco Bay Area.
- Go Flyy , an on-demand, same-day delivery and returns service for fashion, beauty and wellness products, currently operating in Los Angeles, New York City and Seattle.
- Husmus , an online service that aims to make renting easy and affordable in order to build a world where everyone can enjoy renting privately.
- Menther , a digital platform helping to empower and advance women globally through cross and intra-generational mentorship matching and support.
- Storyskimo , an online platform leveraging audio and podcasting as a language and learning development tool for children.
Additionally, as part of HIPP, our Spain office has launched an industry collaborative think tank, Margarita Bly , that is working to pave the way for more female communicators of science, technology and innovation, and encourage more girls and young women to pursue STEM careers.
“We are thrilled to announce the first class of participants in the Hotwire Ignite Possibility Program and look forward to supporting the communications goals of this impressive group of companies,” said Heather Kernahan, Global CEO, Hotwire. “This program is a critical part of Hotwire’s Diversity, Equity, and Inclusion (DEI) strategy to direct more of our resources towards the advancement of social justice in our industry.”
Teams from Hotwire’s global offices will be working with the selected organizations to address their specific business needs through customized programs that include brand strategy, marketing, and public relations services.
“We are honored to be selected as a HIPP participant and so excited to work with a world-class technology communications agency like Hotwire. Children’s Creativity Museum’s mission to nurture creativity and collaboration in all children and families, specifically those in socially and economically disadvantaged communities, is well-aligned with the program goals,” said Carol M. Tang, Ph.D., Executive Director, Children’s Creativity Museum. “We can’t wait to get started.”
“As a female minority co-founder who benefited from mentorship early on in my own career, I’m thrilled to be working with Hotwire to help us scale Menther so more women can have easy access to the power of mentorship,” said Vanessa Villaverde, Menther. “We know this partnership is going to be game changing for us in our reach and impact at a time when women who have been economically impacted by COVID-19 need support the most,” Menther Co-Founder Lesli Ott said.
“We truly believe that no matter who you are or what background you come from, you should be able to access safe and secure housing without having to worry about your credit history or the upfront costs involved,” said Sarah Wernér, Founder of Husmus. “The team and I have worked really hard to create a product that solves a big problem. However, we recognise while we have great technical experience, we do not have the marketing skills to make sure that we are able to reach the many people who need us. Working with Hotwire gives us access to expertise that we otherwise would not have at this early stage and we can’t wait to kick things off,” Husmus’ founder Sarah Wernér said.
About Hotwire
Hotwire is the global technology communication consultancy, part of the Enero Group. Founded in 2000, we operate a worldwide network of wholly owned offices and partners serving a range of clients from scale ups to established multi-nationals. We unleash the possibilities of innovative technology through integrated communications that ignite curiosity, spark action and fuel success. We do this using our proprietary methodology which is underpinned by robust insight and strategy, purposeful creative, integrated planning and a core emphasis on measurement and evaluation. www.hotwireglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005248/en/
Contact information
Kelsey Quickstad
kelsey.quickstad@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
